Vantive's HDx Therapy Proves as Effective as Advanced Dialysis—At Lower Cost

Vantive, a global leader in kidney care, has been delivering over a million patient touchpoints daily for decades. The company, with a 70-year history in organ therapy, continues to develop treatments that simplify care for providers and patients alike. Recent studies now highlight the benefits of its HDx therapy, a more accessible alternative to traditional dialysis methods. Vantive’s HDx therapy uses medium cut-off membranes to match the performance of online hemodiafiltration (OL-HDF). According to Dr. Patricia de Sequera, the treatment delivers comparable results in cardiovascular health and mortality rates. This was confirmed by the MOTheR trial, which found HDx non-inferior to OL-HDF for all-cause death and heart-related events.

The CONCORDIA study further supported these findings, showing HDx therapy met non-inferiority standards in all-cause mortality after adjustments. Beyond clinical outcomes, a Spanish cost analysis revealed practical advantages. HDx therapy reduced resource use, cutting per-session costs by 8% to 18% and lowering water consumption by around 20%. Unlike OL-HDF, HDx does not require extra infrastructure or specialised nurse training. It works with existing hemodialysis equipment, making it a flexible option for clinics. Vantive’s broader mission remains clear: to extend lives and improve care for patients and medical teams worldwide.

The studies reinforce HDx therapy as a viable, cost-effective alternative to OL-HDF. With no need for additional training or equipment, it offers a streamlined approach to dialysis. Vantive’s ongoing innovation continues to shape kidney care, providing solutions that balance efficacy with practicality.